Department of Digestive Surgery, Hôpital Charles Nicolle, Rouen University Hospital, Rouen, France.
Normandie University, UNIROUEN, Inserm U1245, Team 3, IRON group, Rouen University Hospital, Normandy Centre for Genomic and Personalized Medicine, 76000, Rouen, France.
World J Surg. 2018 Jan;42(1):225-232. doi: 10.1007/s00268-017-4163-8.
The incidence of spontaneous rupture of hepatocellular carcinoma (HCC) is low in Europe, at less than 3%. HCC rupture remains a life-threatening complication, with mortality reported between 16 and 30%. The risk of bleeding recurrence has never been clearly evaluated in such clinical situation. The objectives of this study were to evaluate the current risk of mortality related to HCC rupture and to focus on the risk of bleeding recurrence following interventional management.
All patients admitted to 14 French-Italian surgical centers for spontaneous rupture of HCC between May 2000 and May 2012 were retrospectively included. Clinical data, imaging features, relevant laboratory data, treatment strategies, and prognoses were analyzed.
Overall, 58 of the 138 included patients (42%) had cirrhosis. Thirty-five patients (25%) presented with hemorrhagic shock, and 19% with organ(s) dysfunction. Bleeding control was obtained by interventional hemostasis, emergency liver resection, and conservative medical management in 86 (62%), 24 (18%), and 21 (15%) patients, respectively. Best supportive care was chosen for 7 (5%) patients. The mortality rate following rupture was 24%. The bleeding recurrence rate was 22% with related mortality of 52%. In multivariate analysis, a bilirubin level >17 micromol/L (HR 3.768; p = 0.006), bleeding recurrence (HR 5.400; p < 0.0001), and ICU admission after initial management (HR 8.199; p < 0.0001) were associated with in-hospital mortality.
This European, multicenter, large-cohort study confirmed that the prognosis of ruptured HCC is poor with an overall mortality rate of 24%, despite important advances in endovascular techniques. Overall, the rate of bleeding recurrence was more than 20%, with a related high risk of mortality.
欧洲肝细胞癌(HCC)自发性破裂的发病率较低,不到 3%。HCC 破裂仍然是一种危及生命的并发症,死亡率报告在 16%至 30%之间。在这种临床情况下,从未明确评估过再次出血的风险。本研究的目的是评估与 HCC 破裂相关的当前死亡率,并关注介入治疗后再次出血的风险。
回顾性纳入 2000 年 5 月至 2012 年 5 月期间在法国-意大利的 14 家外科中心因自发性 HCC 破裂而住院的所有患者。分析了临床资料、影像学特征、相关实验室数据、治疗策略和预后。
共有 138 例患者中的 58 例(42%)患有肝硬化。35 例(25%)患者出现出血性休克,19%患者出现器官功能障碍。86 例(62%)、24 例(18%)和 21 例(15%)患者分别通过介入止血、紧急肝切除术和保守治疗来控制出血,7 例(5%)患者选择了最佳支持治疗。破裂后死亡率为 24%。出血复发率为 22%,相关死亡率为 52%。多变量分析显示,胆红素水平 >17 μmol/L(HR 3.768;p=0.006)、出血复发(HR 5.400;p<0.0001)和初始治疗后入住 ICU(HR 8.199;p<0.0001)与住院期间的死亡率相关。
这项来自欧洲的多中心大样本研究证实,尽管血管内技术取得了重要进展,但破裂 HCC 的预后仍然很差,总体死亡率为 24%。总的来说,出血复发率超过 20%,相关死亡率较高。